| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.3 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.3 |